AUGS/IUGA Abstract: EnPlace Minimally Invasive
A study of the EnPlace system reported 92.5% patient satisfaction among women aged 33–45.
femselect.comCrawled Nov 9, 2026
A study of the EnPlace system reported 92.5% patient satisfaction among women aged 33–45.
FEMSelect has developed a, meshless medical device to be considered for pelvic organ prolapse without the need for deep dissection.
Pelvic floor reconstructive specialists including urologists, urogynecologists, gynecologists and pelvic floor physiotherapists are invited to receive a peer-reviewed publication about the Neuguide device.
The page discusses pelvic prolapse symptoms, treatment options, surgery, and associated risks.
Find answers about pessary use to relieve symptoms of pelvic organ prolapse.
Boaz has over 20 years of experience in the medical device field. Former CTO of VibeMedic Ltd. and Niti Surgical Solutions Ltd. He is an experienced engineer who has developed numerous clinical devices from concept to market.
Debbie Garner has 20 years of experience leading commercialization for women’s health care products at Eli Lilly and Co. and iMDsoft. She holds an MBA from the Wharton School of Business and a BA from Harvard College.
FEMSelect introduces its leadership team, including CEO Debbie Garner, Founder and Medical Director Menahem Neuman, and Founder and VP of R&D Boaz Harari.
Dr. Karla Loken has extensive experience in medical affairs for global therapeutics and medical device companies, as well as over 20 years in women’s health private practice, education, and academia.
Menahem is currently Head of Urogynecology, Galilee Medical Center and Bar-Ilan University. Prior to this, he was Ethicon Women’s Health & Urology PFR global trainer and Pelvic Floor Innovation Committee Member.
Sherwyn Davidson has over 20 years of experience in medical device quality management and regulatory affairs, including 10 years as Senior Project Manager at Medicsense Ltd.
POP Medical Solutions Ltd. founded. First in Woman clinical study begins.
EnPlace receives 510(k) clearance.
EnPlace Post-Marketing Clinical Study Kickoff. CE Mark obtained.
The company launched EnPlace commercially.
EnPlace Gen2 launched
EnPlace has treated over 3,000 patients.
More than half of women over 50 are living with Pelvic Organ Prolapse. Learn about EnPlace, the minimally invasive approach to Pelvic Organ Prolapse.